Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liquidia Technologies Inc.

www.liquidia.com

Latest From Liquidia Technologies Inc.

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

Financing Business Strategies

IPO Update: Returns Ride Rollercoaster Into Mid-Year As More Biopharmas Take The Plunge

Returns for the 36 biopharma firms that went public in the first half of 2018 – including 14 in June alone – averaged 20.9%, stabilizing after a dip earlier in the year. But while drug developer returns have been on a rollercoaster ride, they're doing better than broader stock indices.

Financing Business Strategies

Pipeline Watch: Phase III Starts With DCC-2618, Tislelizumab And Tabelecleucel

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Execs On The Move, June 2016

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Pulmonary
  • Therapeutic Areas
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Liquidia Technologies Inc.
  • Senior Management
  • Neal F Fowler, CEO
    Kevin Gordon, Pres. & CFO
    Jason Adair, VP, Bus. Dev. & Strategy
    Jeri Thomas, SVP, Commercial
    Benjamin Maynor, PhD, VP, R&D
  • Contact Info
  • Liquidia Technologies Inc.
    Phone: (919) 328-4400
    419 Davis Dr.
    Ste. 100
    Morrisville, NC 27560
    USA
UsernamePublicRestriction

Register